At a glance
ClinicalIndex Comparison Record- ✓Visceral adiposity: waist circumference ≥88 cm for women or ≥102 cm for men AND BMI ≥25 kg/m2
- ✓IGF-I levels within the lowest 2 quartiles for age and gender
- ✓Willingness to maintain current activity level and diet throughout study
- ✕Diabetes mellitus (fasting plasma glucose >126 mg/dL or 2-hour post-OGTT plasma glucose >200 mg/dL)
- ✕Current smoking
- ✕Weight exceeding 280 pounds
- ✕History of cardiovascular disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
In Brief
A clinical study evaluating Nutropin AQ growth hormone and Placebo Growth Hormone for Obesity. Completed, enrolled 142 participants across 1 site.
Detailed Summary
This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin resistance and body composition will be measured.
Study Details
Timeline
Interventions
Participants will give themselves injections of growth hormone every night for 6 months.
Participants will give themselves injections of placebo growth hormone every night for 6 months.